Small-molecule agents for cancer immunotherapy

扫码查看

原文链接

NETL
NSTL
万方数据

外文摘要：Cancer immunotherapy,exemplified by the remarkable clinical benefits of the immune checkpoint blockade and chimeric antigen receptor T-cell therapy,is revolutionizing cancer therapy.They induce long-term tumor regression and overall survival benefit in many types of cancer.With the advances in our knowledge about the tumor immune microenvironment,remarkable progress has been made in the development of small-molecule drugs for immunotherapy.Small molecules targeting PRR-associated pathways,immune checkpoints,oncogenic signaling,metabolic pathways,cytokine/che-mokine signaling,and immune-related kinases have been extensively investigated.Monotherapy of small-molecule immunotherapeutic drugs and their combinations with other antitumor modalities are under active clinical investigations to overcome immune tolerance and circumvent immune checkpoint inhibitor resistance.Here,we review the latest development of small-molecule agents for cancer immunotherapy by targeting defined pathways and highlighting their progress in recent clinical investigations.

外文关键词：

Cancer immunotherapySmall-molecule agentsImmune checkpointsOncogenic signalingMetabolic pathwaysCytokine/chemokine signalingAntitumor immunityTumor immune microenvironment

作者：

Fang Wang、Kai Fu、Yujue Wang、Can Pan、Xueping Wang、Zeyu Liu、Chuan Yang、Ying Zheng、Xiaopeng Li、Yu Lu、Kenneth Kin Wah To、Chenglai Xia、Jianye Zhang、Zhi Shi、Zeping Hu、Min Huang、Liwu Fu

展开 >

作者单位：

State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangdong Esophageal Cancer Institute,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China

School of Pharmaceutical Sciences,Tsinghua-Peking Center for Life Sciences,Beijing Frontier Research Center for Biological Structure,Tsinghua University,Beijing 100084,China

State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China

Department of Cell Biology & Institute of Biomedicine,National Engineering Research Center of Genetic Medicine,MOE Key Laboratory of Tumor Molecular Biology,Guangdong Provincial Key Laboratory of Bioengineering Medicine,College of Life Science and Technology,Jinan University,Guangzhou 510632,China

Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology,NMPA and State Key Laboratory of Respiratory Disease,School of Pharmaceutical Sciences and the Fifth Affiliated Hospital,Guangzhou Medical University,Guangzhou 511436,China

School of Pharmacy,The Chinese University of Hong Kong,Hong Kong 999077,China

Affiliated Foshan Maternity and Child Healthcare Hospital,Southern Medical University,Foshan 528000,China

展开 >

基金：

国家自然科学基金国家自然科学基金国家自然科学基金国家自然科学基金国家自然科学基金Key Project of Science Technology Program of Guangzhou国家重点研发计划广州市科技计划广州市科技计划

项目编号：

U21A20421820738828207331781772540822729962023B03J00292022YFE0209700202201010819202206010081

出版年：

2024

DOI：

10.1016/j.apsb.2023.12.010

药学学报(英文版)

CSTPCD

ISSN：

年,卷(期)：2024.14(3)

参考文献量278